6) Risk management system
- Risk minimisation measures and performance measuring
- Risk communication (DHPC letter, etc.)
- Post-authorisation safety studies (PASS)
Dr Angela van der Salm
DADA Consultancy, Netherlands
Director Pharmacovigilance, Managing partner
In addition to her role as director of the pharmacovigilance department at DADA, Angela also functions as QPPV for several clients, and is the first point of contact for pharmacovigilance enquiries. Angela joined DADA in 2010 and set up the pharmacovigilance department. She holds a PhD in life sciences and previously worked in pharmacovigilance at generic and innovator companies in the pharmaceutical industry.